
Xiaojun Liu
Articles
-
3 weeks ago |
outsourcedpharma.com | Xiaojun Liu |Yeonji Kim |Chris Brown |Jing Zhu |Louis Garguilo
By Xiaojun Liu, Yeonji Kim, Chris Brown, and Jing Zhu Recombinant adeno-associated virus (rAAV) vectors are pivotal in gene therapy due to their proven safety and efficacy for therapeutic gene delivery. However, low production yields and vector heterogeneity remain significant barriers to scalable, high-quality manufacturing.
-
3 weeks ago |
cellandgene.com | Xiaojun Liu |Yeonji Kim |Chris Brown |Jing Zhu
By Xiaojun Liu, Yeonji Kim, Chris Brown, and Jing Zhu Recombinant adeno-associated virus (rAAV) vectors are pivotal in gene therapy due to their proven safety and efficacy for therapeutic gene delivery. However, low production yields and vector heterogeneity remain significant barriers to scalable, high-quality manufacturing.
-
Jan 27, 2025 |
cellandgene.com | Elben Guimaraes |Xiaojun Liu |Junwei Sun |Lucia Fernandez |Lucia Fernández
Each approach has its advantages and drawbacks. This guide should help you decide which one, or perhaps a hybrid strategy, is best for your company. Exploring Strategies For Developing Robust AAV PlatformsExplore advanced AAV production platforms that enhance efficiency, scalability, and compliance, paving the way for safe and accessible gene therapies.
-
Dec 13, 2024 |
mdpi.com | Xiaojun Liu
2. Materials and Methods 2.1. Plant MaterialsA bush-type inbred line, CS82, and a wild-type inbred line, CM82, of pumpkin (C. maxima) were obtained from the high generations of self-crossing in our laboratory. The bush trait of CS82 (C. maxima) was transferred from the spontaneous bush-type mutant of pumpkin (C. moschata) found in Shanxi, China [27]. To analyze the inheritance of the bush trait in pumpkin (C. maxima), bush-type line CS82 and wild-type line CM82 were crossed to construct F1 generation.
-
Nov 22, 2024 |
bioprocessintl.com | Xiaojun Liu |Brian Gazaille |Allan Bream |Tereza Pavlištová
Gene therapies are emerging as promising treatments for previously untreatable genetic disorders, with adeno-associated viruses (AAVs) being the preferred vector for gene delivery. However, AAV-based gene therapies face challenges in production, including cost, complexity, and scalability. With the gene therapy market projected to grow significantly, drug developers are seeking platforms that streamline AAV production.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →